EQL Pharma AB (publ) (NGM:EQL) made an offer to acquire all the remaining stake in Sensidose AB for SEK 91.7 million on April 20, 2023. The shares will be purchased at SEK 7.6 per share. As of April24, 2023, the per share price has been increased to SEK 8.40 per share. The board of directors of Sensidose has assessed the Offer and unanimously recommends Sensidose's shareholders to accept the Offer. The completion of the Offer is conditional upon the Offer being accepted to such extent that EQL Pharma becomes the owner of shares representing more than two thirds of the total number of outstanding shares in Sensidose. The acceptance period for the Offer will commence on April 25, 2023 and expire on May 16, 2023. As of April 26, 2023, The board of EQL Pharma has decided to extend the Offer to include warrants of series TO 1 in Sensidose. The remuneration for the warrants is SEK 0.50. ABG Sundal Collier AB acted as financial advisor to EQL Pharma AB (publ). Markets & Corporate Law Nordic Ab acted as legal advisor to EQL Pharma AB (publ).

EQL Pharma AB (publ) (NGM:EQL) cancelled the acquisition of all the remaining stake in Sensidose AB on May 17, 2023. Due to the fact that the outcome has not met the desired expectations, the Board of Directors of EQL Pharma further announces that it intends to accept Navamedic's offer and sell all its shares and TO 1 in Sensidose.